Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.